STOKE THERAPEUTICS

stoke-therapeutics-logo

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.

#SimilarOrganizations #People #Financial #Event #Website #More

STOKE THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical Therapeutics

Founded:
2014-01-01

Address:
Bedford, Massachusetts, United States

Country:
United States

Website Url:
http://www.stoketherapeutics.com

Total Employee:
101+

Status:
Active

Contact:
781-430-8200

Email Addresses:
[email protected]

Total Funding:
360.1 M USD

Technology used in webpage:
Amazon IPv6 Amazon Oregon Region Akamai Hosted Verizon Greenhouse


Similar Organizations

adamas-pharmaceuticals-logo

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.

arctic-therapeutics-logo

Arctic Therapeutics

Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.

aro-biotherapeutics-logo

Aro Biotherapeutics

Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

geneos-therapeutics-logo

Geneos Therapeutics

Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.

oric-pharmaceuticals-logo

ORIC Pharmaceuticals

ORIC Pharmaceuticals operates as a biopharmaceutical company.

pinpoint-therapeutics-logo

Pinpoint Therapeutics

Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.

scout-bio-logo

Scout Bio

Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.


Current Advisors List

garry-menzel_image

Garry Menzel Board Director @ Stoke Therapeutics
Board_member

aaron-kantoff_image

Aaron Kantoff Board Member @ Stoke Therapeutics
Board_member

arthur-levin_image

Arthur Levin Board Of Directors @ Stoke Therapeutics
Board_member
2015-09-01

Current Employees Featured

edward-kaye_image

Edward Kaye
Edward Kaye CEO & Founder @ Stoke Therapeutics
CEO & Founder
2017-10-01

isabel-aznarez_image

Isabel Aznarez
Isabel Aznarez VP, Biology and Co-Founder @ Stoke Therapeutics
VP, Biology and Co-Founder
2015-12-01

not_available_image

Huw Nash
Huw Nash Founder, COO & CBO @ Stoke Therapeutics
Founder, COO & CBO
2017-10-01

thomas-leggett_image

Thomas Leggett
Thomas Leggett Chief Financial Officer @ Stoke Therapeutics
Chief Financial Officer
2024-05-01

adrian-krainer_image

Adrian Krainer
Adrian Krainer Co-founder & Director @ Stoke Therapeutics
Co-founder & Director
2014-01-01

barry-ticho_image

Barry Ticho
Barry Ticho Chief Medical Officer @ Stoke Therapeutics
Chief Medical Officer

stephen-j-tulipano_image

Stephen J. Tulipano
Stephen J. Tulipano CFO @ Stoke Therapeutics
CFO
2019-03-01

sam-hall_image

Sam Hall
Sam Hall Director @ Stoke Therapeutics
Director
2015-07-01

not_available_image

Jason Hoitt
Jason Hoitt Chief Commercial Officer @ Stoke Therapeutics
Chief Commercial Officer
2024-04-01

Founder


adrian-krainer_image

Adrian Krainer

edward-kaye_image

Edward Kaye

not_available_image

Huw Nash

isabel-aznarez_image

Isabel Aznarez

Stock Details


Company's stock symbol is NASDAQ:STOK

Investors List

alexandria-venture-investments_image

Alexandria Venture Investments

Alexandria Venture Investments investment in Series B - Stoke Therapeutics

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series B - Stoke Therapeutics

rtw-investments-llc_image

RTW Investments

RTW Investments investment in Series B - Stoke Therapeutics

sphera-funds-management_image

Sphera Funds Management

Sphera Funds Management investment in Series B - Stoke Therapeutics

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series B - Stoke Therapeutics

apple-tree-partners_image

Apple Tree Partners

Apple Tree Partners investment in Series B - Stoke Therapeutics

janus-henderson-investors_image

Janus Henderson Investors

Janus Henderson Investors investment in Series B - Stoke Therapeutics

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series B - Stoke Therapeutics

redmile-group_image

Redmile Group

Redmile Group investment in Series B - Stoke Therapeutics

apple-tree-partners_image

Apple Tree Partners

Apple Tree Partners investment in Series A - Stoke Therapeutics

Official Site Inspections

http://www.stoketherapeutics.com Semrush global rank: 2.58 M Semrush visits lastest month: 7.03 K

  • Host name: 184.100.196.35.bc.googleusercontent.com
  • IP address: 35.196.100.184
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Loading ...

More informations about "Stoke Therapeutics"

Corporate Responsibility - Stoke Therapeutics

Stoke cares about building a positive culture both for our employees as well as in our local and patient communities. Our social responsibility efforts include volunteering time and resources โ€ฆSee details»

About Stoke - Stoke Therapeutics

See details»

Stoke Therapeutics - Crunchbase Company Profile

Contact Email [email protected] Phone Number 781-430-8200 Stoke is developing antisense oligonucleotide medicines that target RNA splicing to โ€ฆSee details»

Stoke Therapeutics to Present at the Jefferies Global Healthcare ...

1 day ago BEDFORD, Mass.--(BUSINESS WIRE)--May 29, 2025-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by โ€ฆSee details»

Stoke Therapeutics (STOK) Company Profile & Description - Stock โ€ฆ

Jun 19, 2019 Company profile for Stoke Therapeutics, Inc. (STOK) stock, with a description, list of executives, contact details and other key facts.See details»

Press Releases - Stoke Therapeutics

Feb 26, 2025 Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates. May 13, 2025 โ€“ Regulatory alignment achieved for Phase 3 EMPEROR โ€ฆSee details»

Press Release Details - investor.stoketherapeutics.com

Jan 6, 2025 [email protected] 781-303-8302 Doug Snow Director, Communications & Investor Relations [email protected] 508-642-6485 Source: โ€ฆSee details»

Careers & Culture - Stoke Therapeutics

What Makes Stoke Special. Stoke is a highly collaborative workplace, where mutual respect and admiration, paired with inclusivity, ensure that all team members have the opportunity to make significant contributions to the โ€ฆSee details»

Stoke Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...

May 8, 2025 www.stoketherapeutics.com. Last update 08 May 2025. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. ... The โ€ฆSee details»

Biogen and Stoke Therapeutics Enter into Collaboration to โ€ฆ

Feb 18, 2025 [email protected] 781-303-8302. Doug Snow Director, Communications & Investor Relations [email protected] 508-642-6485. Biogen โ€ฆSee details»

Stoke Therapeutics - VentureRadar

"Stoke Therapeutics (Nasdaq: STOK), is a clinical-stage biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating โ€ฆSee details»

Stoke Therapeutics - Overview, News & Similar companies

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a โ€ฆSee details»

Job Opportunities - Stoke Therapeutics

Those who observe suspicious recruiting activity involving Stoke are encouraged to report it to [email protected] as well as to the Internet Crime Complaint center at โ€ฆSee details»

Pipeline - Stoke Therapeutics

Pipeline. Using the Companyโ€™s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively โ€ฆSee details»

Stoke Therapeutics to Present at the Jefferies Global Healthcare โ€ฆ

1 day ago [email protected] 781-303-8302. Doug Snow Director, Communications & Investor Relations [email protected] 508-642-6485. ๆขๆฌพ ๅŠ ็ง้šฑ โ€ฆSee details»

Press Release Details - investor.stoketherapeutics.com

May 13, 2025 [email protected] 781-303-8302 Doug Snow Director, Communications & Investor Relations [email protected] 508-642-6485 Source: โ€ฆSee details»

Stoke Therapeutics - Work in biotech

Stoke Therapeutics is using new insights in RNA biology to address the underlying cause of severe diseases. Many diseases arise when one copy of a gene functions normally and the โ€ฆSee details»

Scientific Platform - Stoke Therapeutics

A Vision for Our Science. Our novel approach will allow us to pursue disease-modifying treatments for severe diseases. Using the TANGO approach and a deep understanding of โ€ฆSee details»

Press Release Details - investor.stoketherapeutics.com

Dec 31, 2024 โ€“ Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 โ€“ โ€“ As of December โ€ฆSee details»

Press Release Details - Stoke Therapeutics

Jan 10, 2022 โ€“ Establishes co-development and co-commercialization agreement for Stokeโ€™s SYNGAP1 preclinical program โ€“ Acadia receives exclusive worldwide licenses for two โ€ฆSee details»

linkstock.net © 2022. All rights reserved